From ZoomRx, trusted by 19 of the top 20 pharma firms

Built to sharpen your conviction,
Ferma Agents is the best way to create market landscapes

You Own the So What While Agents do the Grunt Work

Catch Early Signals

The best intel isn't in the news. Agents monitor hard-to-reach sources 24/7, scanning 100+ conferences and on-ground Chinese intel so you spot signals others miss.

ClinicalTrials.gov Critical Just now
Phase 3 Primary Endpoint Changed
Oncology Drug-X Competitor Y
SEC Filings Material 12m ago
8-K: Sarepta Announces Strategic Partnership with Roche
Gene Therapy $1.2B Deal
PubMed High Impact 45m ago
Novel resistance mechanism in EGFR+ NSCLC identified
Osimertinib Nature Med
ASCO 2025 Abstract 2h ago
ADC + IO combo shows 42% ORR in refractory solid tumors
Daiichi Sankyo
China Intel Exclusive 4h ago
Hengrui secures NMPA breakthrough for HRS-1167
CLDN18.2 Gastric

Connect Science to Strategy

Stop piecing together data. Agents connect firms, drugs, trials, and commercial strategy, so you can focus on decisions that matter.

Firm
Watch List
Viking Therapeutics
VKTX • $52.34 (+8.2%)
$4.2B Mkt Cap
11mo Runway
"We are evaluating all strategic options to maximize shareholder value" — CEO, Q4 Call
2 Drugs 3 Trials 12 Alerts
Drug
Phase 2b
VK2735
Dual GLP-1/GIP Agonist
14.7% Wt Loss
n=175
"We believe this positions us as best-in-class" — CSO, Investor Day
Viking 2 Trials 5 Competitors
Trial
Met Endpoint
NCT05230989
VENTURE-1 • Obesity
n=469 Enrolled
p<0.001
"We met all primary endpoints with high significance" — CMO, Press Release
VK2735 28 Sites
INSIGHT
Viking exploring strategic alternatives per SEC 8-K
Reuters: Roche, Novo in early discussions
Trial: VK2735 14.7% wt loss at 13wk
SEC: 11mo runway, retained Goldman
SEC Reuters ClinicalTrials
All entities connected — no manual piecing together required

Create Deliverables in Minutes

The last mile is the hardest. Agents turn raw insights into stakeholder-ready decks in your templates, so you can skip the formatting and own the narrative.

Phase 3 data confirms superior efficacy vs SoC

Cross-Trial Analysis ESMO 2025 Benchmarking
Progression-Free Survival HR 0.65
F-202
SoC
p < 0.001
EFFICACY SIGNAL
Confirmed

Achieved stat sig PFS benefit (HR 0.65) vs SoC, outperforming expectations.

SAFETY PROFILE
Clean

Grade 3+ AE rates comparable to placebo. No new safety signals.

INSIGHT
Best-in-class efficacy with p<0.001 across all subgroups. Recommend prioritizing for H1 launch deck.
CLINICAL DEVELOPMENT
SLIDE 1/12

A New Class of Market Intelligence

Feature Cortellis / Evaluate Pharma Ferma Agents
Data Freshness Static snapshots updated periodically Living intelligence, 24/7 monitoring
Conference Intel Abstracts only, limited context Full posters, slides, and sessions
China Coverage Limited western-centric sources On-the-ground native language monitoring
Deliverables Raw data exports you format Finished decks in your templates
Methodology Rigid database filters Your custom playbooks encoded

Try Ferma Agents Now